38
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Monitoring the SPREAD of the SARS-CoV-2 lineage B.1.621 in Udine, Italy

      letter

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction Since October 2020, the emergence of novel lineages of SARS-CoV-2 is generating widespread concern.1 They are characterised by distinct genetic features that might lead to increased transmissibility and/or immune evasion from previous infection or vaccination.2 Therefore, genomic surveillance gains and increasingly important role to track the emergence, the spread and the transmissibility of these lineages.3 Our unpublished data demonstrated the fast spread of the B.1.1.7 ((WHO)-designated variant of concern Alpha) lineage in our territory, reaching the 100% prevalence in about 2 months. The University Hospital of Udine is the hub that serves the former province of Udine (Italy) and, between April and May 2021, it processed 97 000 nasopharyngeal swabs. Specimens resulted positive with standard molecular biology techniques (Allplex SARS-CoV-2 Assay by Seegene) were analysed by high-resolution melting (HRM) to evaluate the presence of specific variants on the Spike glycoprotein (p.E484K/Q, p.N501Y, p.L452R, p.K417N/T, p.P681H) considered key features of almost all the novel identified lineages and/or associated with the lack of response to monoclonal antibodies and convalescent plasma treatments.4 About 370 positive samples with Ct values ≤28 (3.81% of total positive samples) were randomly selected and subsequently underwent next-generation sequencing (NGS) to establish their belonging lineage, in order to manage local public health responses and reorganise hospitalisation. Amplicon-based sequencing was performed on an Ion GeneStudio S5 system (Thermo Fisher Scientific). Sequences kept for further investigations were the ones possessing a mean depth of coverage ≥500 and a percentage of gaps≤20% of the entire sequence. For variant calling, variants with a genotype quality score ≥30, a coverage (flow total depth at position (FDP)) ≥500 and a minimum alternate allele frequency of 70% (≥70%) were kept for further investigations. FASTA sequences were analysed with the Phylogenetic Assignment of Named Global Outbreak Lineages (PANGOLIN) web tool developed by the Centre for Genomic Pathogen Surveillance (https://pangolin.cog-uk.io/) and the Ultrafast Sample placement on Existing tRee (UShER) web tool by the University of California Santa Cruz (UCSC) genome browser (https://genome.ucsc.edu/cgi-bin/hgPhyloPlace). We identified 13 samples displaying an uncommon genotype, classified as B.1.621. It originates from the B.1 lineage and the shared genomic features harboured by our cluster are enlisted in table 1. Table 1 List of shared mutations of the SARS-COV-2 B.1.621 lineage isolated in the North East of Italy Nucleotide Reference Alteration Gene Amino acid change 241 C T . . 3037 C T orf1ab p.Phe924Phe 3428 A G orf1ab p.Thr1055Ala 4878 C T orf1ab p.Thr1538Ile 6037 C T orf1ab p.Ser1924Ser 10 029 C T orf1ab p.Thr3255Ile 11 451 A G orf1ab p.Gln3729Arg 13 057 A T orf1ab p.Ser4264Ser 14 408 C T orf1ab p.Pro4715Leu 17 491 C T orf1ab p.Pro5743Ser 18 877 C T orf1ab p.Leu6205Leu 19 035 T C orf1ab p.Ile6257Ile 20 148 C T orf1ab p.Phe6628Phe 21 990 T TTAC S p.Val143ValThr 21 993 A C S p.Tyr144Ser 21 995 T A S p.Tyr145Asn 22 599 G A S p.Arg346Lys 23 012 G A S p.Glu484Lys 23 063 A T S p.Asn501Tyr 23 403 A G S p.Asp614Gly 23 604 C A S p.Pro681His 24 410 G A S p.Asp950Asn 25 563 G T ORF3a p.Gln57His 26 157 TGTTA T ORF3a p.Val256fs 26 492 A T . . 27 925 C A ORF8 p.Thr11Lys 28 005 C T ORF8 p.Pro38Ser 28 272 A T N . 28 887 C T N p.Thr205Ile 29 781 G T . . Ten out of 13 sequences have been shared in the GISAID database (EPI_ISL_2613608, EPI_ISL_2613609, EPI_ISL_2613606, EPI_ISL_2613607, EPI_ISL_2613611, EPI_ISL_2613610, EPI_ISL_2613604, EPI_ISL_2613605, EPI_ISL_2613602, EPI_ISL_2613603). The remaining three were omitted due to quality criteria, although B.1.621 assignment was confirmed by both PANGOLIN and UShER online tools. As evidenced in figure 1A, our samples overlap with the other B.1.621 sequences in Nextclade V.2.29.1web application (https://clades.nextstrain.org/). To better characterise whether the 10 genomes analysed displayed some differences, we performed a phylogenetic analysis with Molecular Evolutionary Genetics Analysis V.11 using the maximum Likelihood method (Tamura-Nei method). Although few, samples cluster into two main subgroups (figure 1B). Figure 1 Phylogenetic analysis of B.1.621 samples. (A) Clades distribution according to the Nextclade online tool. Our sequences are represented as big red dots. (B) Phylogenetic tree of the 10 B.1.621 sequences based on the maximum likelihood method of MEGA V.11. Created with Biorender.com. FVG, Friuli Venezia Giulia; MEGA, Molecular Evolutionary Genetics Analysis. Since epidemiological or in vitro evidences on the impact of this lineage on transmissibility, severity and/or immunity are by far preliminary, we promptly traced subjects who came into contact with the members of our cohort to prevent a putative outbreak and to avoid the possible spread of this lineage in our territory. Indeed, this lineage has been identified in early January 2021 in Colombia,5 and it has been associated to sporadic infections due to contacts with travellers. It has been enlisted within the seven variants of interest by the European Centre for Disease Prevention and Control), in the ‘Situation updates on COVID-19’ document of 24 June.6 Furthermore, 624 sequences referring to this lineage have been deposited in the PANGOLIN database (https://cov-lineages.org/lineages/lineage_B.1.621.html). Our data document the first cluster of B.1.621 infections in Italy. Given the rapid spread and the ability of viruses harbouring the p.E484K to escape from neutralising antibodies, this study emphasise the importance of monitoring the circulation of this strain and other variants of interest.2 Indeed, HRM-based screening is mandatory to early identify uncommon genotypes within the area of interest in order to both forewarn local healthcare facilities and prioritise NGS sequencing.7 Noteworthy, since January 2021, our approach allowed us to identify subjects infected by diverse lineages, such as B.1, B.1.1.7, B.1.177, B.1.221, B.1.258, B.1.1.317, B.1.1.318, C.17 (unpublished data). Focusing on data belonging to the timespan covered by this study, four major lineages were present in the ex-province of Udine. It is likely to assume that the occurrence of the lineages with lower frequency in our territory is attributable to international travels. These data are summarised in figure 2. Figure 2 Lineage distribution across samples underwent next-generation sequencing between April and May 2021 in Friuli Venezia Giulia. B.1.177: 0.55%; B.1.258: 0.27%; P.1: 0.55%; C.36.3: 1.64%; B.1.620: 0.27%; B.1.621: 3.55%; B.1.1.7: 93.17%. Discussion In this analysis, we highlighted the local occurrence of SARS-CoV-2 lineages in the former province of Udine (Italy). Since March 2021, the prevalent variant in Friuli Venezia Giulia is the Alpha one, known to have a substantial transmission advantage over other lineages.8 Nonetheless, we witnessed the occurrence of a small percentage of variants of interest or variants under monitoring, mostly introduced by travellers. In this subgroup, the main lineage is represented by the B.1.621, being the 62.5% of the non-alpha ones. The cluster we were able to track was mostly composed by individuals of South American origin (ie, Bolivia, Argentina and Colombia). Only one patient was hospitalised due to COVID-19 but discharged after 2 days with a diagnosis of mild pneumonia, the remaining being paucisymptomatic. Notwithstanding, this report is flawed by the fact that a disclosure of interpersonal contacts was made on a voluntary basis, and therefore, the information may not be entirely reliable, hence, additional instances of transmission might have been missed. Despite limitations, these findings have serious implications for public health agencies responding to SARS-CoV-2 variants of concern. Our data show that prompt contact tracing of confirmed cases and extensive collection of nasal swabs from close contacts, coupled to isolation or quarantine for SARS-CoV-2 infected subjects, can be effective in extinguishing local outbreaks. Genetic surveillance programmes must be indeed improved and implemented for the rapid detection and tracking of novel lineages, that is, B.1.621, in order to control their spread and alert public health authorities.

          Related collections

          Most cited references8

          • Record: found
          • Abstract: found
          • Article: found

          Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2

            SARS-CoV-2 genetic diversity has the potential to impact the virus transmissibility and the escape from natural infection- or vaccine-elicited neutralizing antibodies. Here, we report the emergence of the B.1.621 lineage, considered a variant of interest (VOI) with the accumulation of several substitutions affecting the Spike protein, including the amino acid changes I95I, Y144T, Y145S and the insertion 146 N in the N-terminal domain, R346K, E484K and N501Y in the Receptor Binding Domain and P681H in the S1/S2 cleavage site of the Spike protein. The rapid increase in frequency and fixation in a relatively short time in some cities that were near the theoretical herd immunity suggests an epidemiologic impact. Further studies will be required to assess the biological and epidemiologic roles of the substitution pattern found in the B.1.621 lineage.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.

              One year in the coronavirus disease 2019 (COVID-19) pandemic, the first vaccines are being rolled out under emergency use authorizations. It is of great concern that newly emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can escape antibody-mediated protection induced by previous infection or vaccination through mutations in the spike protein. The glutamate (E) to Lysine (K) substitution at position 484 (E484K) in the receptor binding domain (RBD) of the spike protein is present in the rapidly spreading variants of concern belonging to the B.1.351 and P.1 lineages. We performed in vitro microneutralization assays with both the USA-WA1/2020 virus and a recombinant (r)SARS-CoV-2 virus that is identical to USA-WA1/2020 except for the E484K mutation introduced in the spike RBD. We selected 34 sera from study participants based on their SARS-CoV-2 spike ELISA antibody titer (negative [N=4] versus weak [N=8], moderate [N=11] or strong positive [N=11]). In addition, we included sera from five individuals who received two doses of the Pfizer SARS-CoV-2 vaccine BNT162b2. Serum neutralization efficiency was lower against the E484K rSARS-CoV-2 (vaccination samples: 3.4 fold; convalescent low IgG: 2.4 fold, moderate IgG: 4.2 fold and high IgG: 2.6 fold) compared to USA-WA1/2020. For some of the convalescent donor sera with low or moderate IgG against the SARS-CoV-2 spike, the drop in neutralization efficiency resulted in neutralization ID50 values similar to negative control samples, with low or even absence of neutralization of the E484K rSARS-CoV-2. However, human sera with high neutralization titers against the USA-WA1/2020 strain were still able to neutralize the E484K rSARS-CoV-2. Therefore, it is important to aim for the highest titers possible induced by vaccination to enhance protection against newly emerging SARS-CoV-2 variants. Two vaccine doses may be needed for induction of high antibody titers against SARS-CoV-2. Postponing the second vaccination is suggested by some public health authorities in order to provide more individuals with a primer vaccination. Our data suggests that this may leave vaccinees less protected against newly emerging variants.
                Bookmark

                Author and article information

                Journal
                J Clin Pathol
                J Clin Pathol
                jclinpath
                jcp
                Journal of Clinical Pathology
                BMJ Publishing Group (BMA House, Tavistock Square, London, WC1H 9JR )
                0021-9746
                1472-4146
                October 2022
                15 December 2021
                15 December 2021
                : 75
                : 10
                : 712-714
                Affiliations
                [1 ] departmentDepartment of Medicine (DAME) , University of Udine , Udine, Italy
                [2 ] departmentDepartment of Laboratory Medicine , Udine University Health Integrated Agency , Udine, Italy
                [3 ] departmentClinic of Infectious Diseases , Udine University Health Integrated Agency , Udine, Italy
                Author notes
                [Correspondence to ] Professor Francesco Curcio, Udine University Health Integrated Agency, Udine, Friuli-Venezia Giulia, Italy; francesco.curcio@ 123456asufc.sanita.fvg.it

                CM and CDS are joint first authors.

                Author information
                http://orcid.org/0000-0002-1906-3074
                Article
                jclinpath-2021-207810
                10.1136/jclinpath-2021-207810
                9510432
                34911747
                c78dda90-d275-4895-a6bc-99a5d0deec8d
                © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

                This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:  http://creativecommons.org/licenses/by-nc/4.0/.

                History
                : 08 July 2021
                : 21 November 2021
                Categories
                PostScript
                2474
                1506
                Correspondence
                Custom metadata
                unlocked

                Pathology
                covid-19,epidemiology,molecular biology
                Pathology
                covid-19, epidemiology, molecular biology

                Comments

                Comment on this article